article thumbnail

AI in Pharmaceuticals: From Discovery to Market

Complex Discovery

Editor’s Note: Artificial intelligence (AI) is transforming the pharmaceutical industry, offering unprecedented opportunities to accelerate drug discovery, streamline clinical trials, and fortify intellectual property (IP) strategies.

article thumbnail

CAFC Orders Review of Extrinsic Evidence to Determine Proper Limit of Claimed pH Range

IP Watchdog

Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Actelion Pharmaceuticals Ltd. Mylan Pharmaceuticals Inc. The Federal Circuit remanded the case for further consideration of extrinsic evidence from chemistry textbooks to determine the proper meaning of the claim term “a pH of 13 or higher.”

Evidence 106
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What Recent Case Law Tells Us About the Importance of Consumer Surveys in Trademark Cases

IP Watchdog

District Court for the Southern District of Florida ruled against plaintiff Vital Pharmaceuticals, Inc.’s In each of these opinions, the court noted the absence of survey evidence (or, in the Vital Pharmaceuticals case, the inadequacy of an “almost comically flawed” survey). On August 3, 2021, the U.S. On June 7, 2021, the U.S.

Case Law 127
article thumbnail

Other Barks & Bites for Friday, March 7: Lashify Wins ITC Appeal on Economic Prong Analysis; CAFC Says Apple Did Not Violate Discovery Obligations at PTAB; and ParkerVision Files Reply Brief on Rule 36 Appeal at SCOTUS

IP Watchdog

International Trade Commissions economic prong analysis for the domestic industry requirement of Section 337, finding that petitioners at the Patent Trial and Appeal Board have no self-executing discovery obligations to present evidence from parallel ITC proceedings, and more; strong global demand for AI chips buoys Broadcoms first quarter results; (..)

article thumbnail

SCOTUS Scraps Vanda’s Bid for Guidance on Obviousness Standard

IP Watchdog

Vanda Pharmaceuticals filed the petition following the U.S. The CAFC came to its decision in part because the court said the disclosure of clinical trials was evidence that a person of ordinary skill in the art “would have had a reasonable expectation of success.”

article thumbnail

Ninth Circuit Denies Review of Decision that IPR Proceedings Do Not Trigger FCA’s Public Disclosure Bar

IP Watchdog

The FCA claim was brought by patent attorney Zachary Silbersher against Valeant Pharmaceuticals, predecessor to Canadian drugmaker Bausch Health.

article thumbnail

CAFC Reverses January Decision Affirming Sufficient Written Description for Negative Claim Limitation Over Judge Linn’s Dissent

IP Watchdog

Court of Appeals for the Federal Circuit issued a precedential decision in Novartis Pharmaceuticals Corp. Earlier today, the U.S. Accord Healthcare, Inc. granting a petition for rehearing from appellant HEC Pharm Co.,